Anti-IgE therapy: current knowledge and future perspective

R. Buhl (Mainz, Germany)

Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now?
Session: The journey towards personalized medicine in asthma: where are we now?
Session type: Evening Symposium
Number: 3467
Disease area: Airway diseases

Webcast

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Buhl (Mainz, Germany). Anti-IgE therapy: current knowledge and future perspective. International Congress 2019 – The journey towards personalized medicine in asthma: where are we now?

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Anti-IgE therapy: rationale and clinical evidence
Source: Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives
Year: 2007

Biologics: current use and future applications for personalised therapy
Source: Virtual Congress 2021 – Wheezing illnesses along the life span
Year: 2021


Clinical trial landscape for M/XDR-TB: current evidence and future perspectives
Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis
Year: 2019


In the era of personalized medicine, what are the current unmet needs in asthma?
Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now?
Year: 2019

Other options of prevention - the current state and the future
Source: Annual Congress 2003 - Latent tuberculosis infection - preventive approaches
Year: 2003

The microbiome in respiratory medicine: current challenges and future perspectives
Source: Eur Respir J , 49 (4)  1602086; DOI: 10.1183/13993003.02086-2016
Year: 2017



Device-generated data: current knowledge and perspectives
Source: 5th Sleep and Breathing Conference
Year: 2019

At the interface: the translational science supporting the clinical use of anti-cytokine therapy
Source: International Congress 2018 – New biologics for asthma: which patients, which agents, which results, at what cost?
Year: 2018


Anti-IgE: changing lives in clinical practice?
Source: Eur Respir Rev 2007; 16: 59-60
Year: 2007


Lung function trajectory research: historical perspective and future prospects
Source: Research Seminar 2021 – Lung function trajectories from birth to death, health and disease, and pre-war to today
Year: 2021



Value of animal models. Lessons learnt from another therapeutic area: implications for respiratory disease
Source: Annual Congress 2007 - PG11 - Translation of animal models to human airway disease
Year: 2007



Halotherapy and Covid-19: an oppinion for a possible future prevention approach
Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors
Year: 2021


Introduction: CPET in clinical practice. Recent advances, current challenges and future directions
Source: Eur Respir Monogr 2018; 80: x-xxv
Year: 2018

The concept of control in COPD: a new proposal for optimising therapy
Source: Eur Respir J 2014; 44: 1072-1075
Year: 2014


NORDSTAR: paving the way for a new era in asthma research
Source: Eur Respir J, 55 (4) 1902476; 10.1183/13993003.02476-2019
Year: 2020



Therapeutic management - Current status and future developments
Source: COVID-19 Videos
Year: 2020

New and future developments of therapy for asthma in children
Source: Eur Respir Mon 2012; 56: 224-234
Year: 2012